# Proteogenomic Translational Research Center for Clinical Proteomic

> **NIH NIH U01** · BATTELLE PACIFIC NORTHWEST LABORATORIES · 2020 · $1,370,852

## Abstract

PROJECT SUMMARY
The Pacific Northwest Proteogenomic Translational Research Center (PNPTRC) has two overarching aims:
1) to use combined measurements of protein abundance and post translational modifications, particularly
phosphorylation, to build predictive models of drug response that can be effectively used to guide the choice of
agents for first-line therapies, and 2) to model the processes of signaling crosstalk and redundancy to more
effectively predict drug resistance and to guide second line therapies. To accomplish these goals, the
PNPTRC will leverage on-going preclinical and clinical studies of individualized treatment selection strategies
for acute myelogenous leukemia (AML) to improve the emerging models based on DNA and RNA data to
include signal transduction pathway information derived from proteomic and phosphoproteomic
measurements, and improve the predictive power of the models by integrating genomic and proteomic data.
The PNPTRC represents a collaboration between innovative clinical trial design and therapeutic interventions
at the OHSU Knight Cancer Center, and cutting edge mass spectrometry-based proteomics technologies at
PNNL. The Preclinical Research Arm of the PNPTRC will identify differences in protein abundance and protein
phosphorylation that correlate strongly with cell survival in the in vitro IC50 assay developed at OHSU.
Measurements of protein abundance and phosphorylation over time of treatment will be used to build networks
of pathway activation and crosstalk that can inform the likelihood of eventual resistance and identify alternative
signaling pathways which can be targeted in second line therapies. The models will be further tested and
refined in subsequent ex vivo experiments using primary human AML cells exposed to specific combinations of
inhibitors. The Clinical Research Arm will apply high quality targeted proteomic assays on samples from AML
patients enrolled in NCI-sponsored clinical trials to confirm the predictive abilities of specific differences in
protein abundance and/or phosphorylation identified in the Preclinical Research Arm.

## Key facts

- **NIH application ID:** 9950845
- **Project number:** 5U01CA214116-04
- **Recipient organization:** BATTELLE PACIFIC NORTHWEST LABORATORIES
- **Principal Investigator:** BRIAN J DRUKER
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,370,852
- **Award type:** 5
- **Project period:** 2017-06-08 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9950845

## Citation

> US National Institutes of Health, RePORTER application 9950845, Proteogenomic Translational Research Center for Clinical Proteomic (5U01CA214116-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9950845. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*